Related Experiment Video
Updated: Jul 3, 2026
07:35
Determining Bile Duct Density in the Mouse Liver
Published on: April 30, 2019
Transient hepatic attenuation difference (THAD) in biliary duct disease.
Silvia Pradella1, Nicoletta Centi, Giorgio La Villa
1Department of Clinical Physiopathology, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Italy.
Abdominal Imaging
|August 7, 2008
Summary
The study found that specific patterns of tumorlike arterial enhancement (THADs) are significantly associated with various biliary diseases, aiding in their imaging assessment. Evaluating THADs can enhance diagnosis for conditions like biliary duct dilation, cholangiocarcinoma, and cholangitis.
Area of Science:
- Radiology
- Hepatobiliary Imaging
- Vascular Imaging
Background:
- Tumorlike arterial enhancement (THADs) are linked to diverse hepato-biliary conditions.
- Accurate imaging assessment is crucial for diagnosing biliary diseases.
- Understanding THADs' role can improve diagnostic capabilities.
Purpose of the Study:
- To investigate the role of THADs in the imaging assessment of biliary diseases.
- To determine the frequency and patterns of THADs in specific biliary pathologies.
- To establish the diagnostic utility of THADs in clinical practice.
Main Methods:
- Retrospective analysis of 1833 upper abdomen biphasic CT scans (2003-2007).
- Inclusion of patients with biliary duct dilation (n=20), cholangiocarcinoma (n=19), and cholangitis (n=14).
- Comparison with a control group (n=1124) without liver/biliary pathology; assessment of THAD presence and patterns.
Main Results:
- THADs were present in 67.9% of study patients versus 1.78% in controls (P < 0.0001).
- Peribiliary-THADs correlated with biliary duct dilation (55%).
- Sectorial-THADs correlated with cholangiocarcinoma (79%), and polymorphous-THADs with cholangitis (71%).
Conclusions:
- THADs are complex but valuable imaging indicators in biliary pathology.
- Specific THAD patterns demonstrate significant correlation with distinct biliary diseases.
- Evaluation of THADs can serve as an additional diagnostic tool for biliary conditions.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:14Hepatic Drug Clearance: Role of Transporters
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...